Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05156125 is registered in ClinicalTrials.gov with Oppilan Pharma Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Lead sponsor
- Oppilan Pharma Ltd
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2021
- Completion date
- March 13, 2025
- Enrollment
- 213 (actual)
- Sites
- 77
Conditions
As the registry lists them; a condition with its own page is linked.